Revvity, Inc. (RVTY) Earnings Call Transcripts
Revvity, Inc.'s Latest Earnings Call - September 15, 2026
In the second quarter of fiscal year 2026, Revvity, Inc. reported better-than-expected performance with revenue and earnings exceeding management's prior guidance. Revenue for the quarter was $150 million, reflecting a 5% increase year-over-year, while earnings per share (EPS) came in at $0.45, beating estimates by $0.05. Management raised guidance for the Diagnostics segment to high single digits, driven by strong growth in reproductive health and immunodiagnostics, despite challenges in the Life Sciences segment, which is expected to improve in the latter half of the year due to a significant backlog in instrument orders.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $150M (beat) |
| EPS | $0.45 (beat) |
| Diagnostics Growth | 11% (positive) |
| Life Sciences Organic Growth | -3% (negative) |
| Backlog | Strongest in 3-5 years (positive) |
| China Reagents Growth | Double-digit (positive) |
Guidance from management
Management raised full-year guidance for the Diagnostics segment to high single digits, while Life Sciences instruments are expected to grow mid-single digits in Q3 and Q4 due to backlog conversion.
What management said
Yes. Unfortunately, I'm not going to provide specifics on that. But I would say we have been seeing demand from both improvement in demand from both traditional as well as nontraditional customers. I would say the uptick or inflection in orders is probably more from traditional customers than it is from nontraditional customers, but the nontraditional customers, I think, is not insignificant and it's new. So I think ...
What analysts pressed on
Analysts expressed concerns regarding the significant decline in Life Sciences organic growth and the potential impact of contract timing on future performance. There were also questions about the sustainability of growth in the Diagnostics segment amid broader market pressures.
Main topics on the call
- Strong Diagnostics Growth — Revvity's Diagnostics segment accelerated growth from 9% in Q1 to 11% in Q2, driven by 'better growth in both the reproductive health side of diagnostics as well as immunodiagnostics.' Management raised full-year guidanc...
- Life Sciences Segment Challenges — The Life Sciences segment faced a decline in organic growth from 3% in Q1 to negative 3% in Q2, attributed to 'contract timing issues' and tough comparisons. However, management noted a strong backlog that should support...
- Backlog and Future Growth — Management highlighted the 'strongest backlog' seen in 3-5 years, particularly in high-content screening instruments. This backlog is expected to convert into mid-single-digit growth in Q3 and Q4, signaling potential rec...
- AI Product Launches — 2026 is positioned as a pivotal year for new product launches, including AI-driven offerings. Management indicated that while contributions to revenue may be 'fairly nominal' in the short term, these innovations could si...
Read the full Revvity, Inc. transcript (September 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Revvity, Inc.
Revvity, Inc. (RVTY) is a publicly listed company in the Life Sciences Tools and Services industry, within the Health Care sector. It trades on NYSE and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 93 calls on record spanning January 14, 2020 to September 15, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 93 Revvity, Inc. earnings call transcripts on record, spanning January 14, 2020 to September 15, 2026. Based on this history, Revvity, Inc. reports quarterly. The most recent call on file is dated September 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- RVTY
- Exchange
- NYSE
- Country
- US
- Sector
- Health Care
- Industry
- Life Sciences Tools and Services
- Calls on record
- 93
- First call
- January 14, 2020
- Most recent
- September 15, 2026
- Reporting cadence
- quarterly